Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
Status:
Completed
Trial end date:
2021-07-18
Target enrollment:
Participant gender:
Summary
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in
Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the
potential of opaganib to improve and/or stabilize the clinical status of the patient.